EUCTR2006-001307-11-DE进行中（未招募）不适用
A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN). - NA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •· Male or female of any race at least 18 years of age.
- •· Female patients must be postmenopausal, or surgically sterilized, or (if they are of childbearing potential) they must be nonpregnant and nonlactating and must be using appropriate methods of contraception (including barrier or hormonal method). Women of childbearing potential must have a confirmed negative urine pregnancy test at the screening visit (V1) and at the randomization visit (V2).
- •· Diagnosis of type 1 or 2 diabetes mellitus (by American Diabetic Association Clinical Practice Recommendations diagnostic criteria www.diabetes.org) for at least 1 year; Hemoglobin A1c levels of =11% at V1 (with fluctuations of =1% in the three months prior to this, established by comparison of V1 HbA1c result with an HbA1c result obtained between 6-12 weeks before V1) and at V1 completion of a diabetes treatment checklist (see Appendix A), demonstrating optimal diabetic control.
- •· Diagnosis of painful, distal, symmetrical, sensorimotor polyneuropathy, which is due to diabetes, for at least 1 year.
- •· Patients at V1 must have a score =40 mm on the Pain Visual Analogue Scale (VAS).
- •· Normal chest x-ray within 1 year prior to V1; or stable x-ray defined as no clinically significant change from previous exam (if none available, x-ray must be taken at V1).
- •· Patients must be able to understand and cooperate with trial procedures, and have signed a written informed consent prior to entering the trial.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •· Malignancy within the past 2 years with the exception of basal cell carcinoma.
- •· Patients with significant hepatic impairment (i.e. AST/ALT > 2x ULN, Total bilirubin >2 x ULN).
- •· Clinically significant abnormal 12-lead ECG (in the opinion of the investigator).
- •· Neurological disorders unrelated to diabetic neuropathy that may confuse the assessment of neuropathic pain.
- •· Any pain or other condition that may confound assessment or self-evaluation of the pain due to diabetic neuropathy.
- •· History of chronic hepatitis B or C, acute hepatitis A, B or C within the past 3 months, or HIV infection.
- •· Skin conditions in the area affected by the neuropathy that (in the opinion of the investigator) could alter sensation.
- •· Amputations other than toes.
- •· Administration of any investigational drug and/or agent within 30 days prior to screening.
- •· Use of prohibited medications, in the absence of appropriate washout phases.
- •· Abuse of drugs or alcohol within the last 2 years.
- •· Any serious or unstable medical conditions that, in the opinion of the investigator, would compromise participation in the trial.
- •· Any history of, or current, significant psychiatric disorder e.g. any DSM-IV Axis I or II Disorder or patients judged clinically to be a serious suicidal risk.
- •· History of recurrent syncope or hypotension (systolic <90mmHg, diastolic <40mmHg).
- •· Postural hypotension (a fall of 20mmHg in systolic BP or 10mmHg in diastolic BP on standing).
- •· History of transient ischemic attack or stroke.
- •· Carotid bruit, unless significant carotid stenosis (e.g. >70%) has been excluded by appropriate investigation.
- •· History of uncontrolled narrow angle glaucoma.
- •· History of a seizure disorder, including acute epilepsy requiring treatment, alcoholic seizures, a family history of seizures or a history of head traumata that resulted in loss of consciouness or concussion.
- •· Previous exposure to reboxetine.
- •· History of urinary retention or prostatic hypertrophy (unless surgically corrected e.g. by TURP).
- •· History of heart failure (NYHA class =2), acute myocardial infarction (onset less than previous 3 months), or unstable angina.
研究者
相似试验
进行中（未招募）
不适用
A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH CHRONIC PAINFUL DIABETIC PERIPHERAL NEUROPATHY (DPN). - NADiabetic Peripheral NeuropathyEUCTR2006-001307-11-EEPfizer Luxembourg SARL Branch Office Estonia800
进行中（未招募）
不适用
A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). - N/APostherpetic neuralgiaMedDRA version: 8.1Level: LLTClassification code 10029223Term: NeuralgiaEUCTR2006-001343-55-LTPfizer Luxembourg SARL Branch Office in Lithuania600
进行中（未招募）
不适用
A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). - N/APostherpetic neuralgiaMedDRA version: 8.1Level: LLTClassification code 10029223Term: NeuralgiaEUCTR2006-001343-55-SEPfizer Ltd600
进行中（未招募）
1 期
A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN). - N/APostherpetic neuralgiaMedDRA version: 8.1Level: LLTClassification code 10029223Term: NeuralgiaEUCTR2006-001343-55-GBPfizer Ltd600
进行中（未招募）
1 期
A PHASE 2B LONG-TERM, RANDOMIZED, OPEN-LABEL, SAFETY AND TOLERABILITY TRIAL COMPARING [S,S]-REBOXETINE (PNU-165442G) WITH ROUTINE CARE IN PATIENTS WITH POSTHERPETIC NEURALGIA (PHN).EUCTR2006-001343-55-ESPfizer, S.A.600